Weight Loss / Metabolic — fat loss & metabolic reset
Physician-supervised metabolic protocols targeting visceral fat, appetite regulation, and insulin sensitivity — built around the latest GLP-1 and dual/triple agonist therapies with peptide adjuncts for lean mass preservation.
What patients commonly experience on this protocol, based on research and clinical application.
Significant Fat Reduction
Substantial and sustained loss of body fat, including visceral adipose tissue, under structured medical monitoring.
Appetite & Craving Control
Reduced hunger signals and improved satiety, making caloric adherence more sustainable long-term.
Metabolic Flexibility
Improved insulin sensitivity, glucose handling, and overall metabolic markers tracked via labs.
Muscle-Sparing Support
When paired with resistance training and adequate protein, supports lean mass preservation during fat loss.
Cardio-Metabolic Gains
Favorable shifts in triglycerides, ApoB, and inflammatory markers commonly observed with GLP-1/GIP pathways.
Sustainable Protocol Design
Titration, cycling options, and combination strategies individualized to patient response and goals.
⚗
Compounds & Protocols
All prescriptions are individualized, physician-supervised, and compounded to clinical standards.
Compound
Protocol details & benefit
Semaglutide
GLP-1 receptor agonist with robust evidence for weight loss (avg 15–17% body weight). Improves HbA1c, cardiovascular risk markers, and metabolic inflammation.
Tirzepatide
Dual GIP/GLP-1 agonist with superior outcomes vs GLP-1 monotherapy (avg 20–22%). Significant improvements in insulin sensitivity and lipid panels.
Retatrutide
Triple agonist (GLP-1, GIP, glucagon). Emerging data shows up to 24% body weight reduction. Strong visceral and hepatic fat reduction. Used under close monitoring.
Cagrilintide
Long-acting amylin analogue that complements GLP-1 therapy by targeting a separate satiety pathway. Synergistic appetite control when combined with semaglutide.
AOD-9604
GH fragment that stimulates lipolysis without anabolic or insulin-resistance effects of full GH. Specifically targets fat cells without affecting IGF-1.
Medical disclaimer: All protocols at Juvatide are prescribed and supervised by licensed physicians. Compounds and dosing schedules are individualized based on comprehensive lab work and patient history. Information on this page is educational and does not constitute medical advice. Compounded peptides are not FDA-approved drugs. Results vary by individual.
